Biohaven shares rise after FDA accepts Vyglxia resubmission for ataxia
Biohaven said in an SEC filing that the FDA accepted its resubmitted application for Vyglxia (troriluzole) in spinocerebellar ataxia. The shares rose.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Biohaven Ltd. said in a filing with the SEC that the U.S. Food and Drug Administration has accepted its resubmitted application for Vyglxia, whose active ingredient is troriluzole, for the treatment of spinocerebellar ataxia.
Seeking Alpha reported that Biohaven's shares surged after the announcement.
why it matters
Acceptance means the drug moves to the next stage of regulatory review, which is why biotech stocks often react sharply to news like this. The development concerns a single issuer and is unlikely to affect the broader market.
tags
instruments
sources
- Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA — Reuters, 22 October 2026 at 12:02 UTC
- Biohaven surges as FDA accepts resubmission for Vyglxia for spinocerebellar ataxia — Seeking Alpha, 22 October 2026 at 13:27 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗